Michel G D Kester

8PUBLICATIONS
56CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityProteins and peptidesEmergency medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 19, 2025
TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer.

Rosa A van Amerongen, Sander Tuit, Dennis F G Remst

|Mar 01, 2024
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.

Kyra J Fuchs, Marian van de Meent, M Willy Honders

|Nov 24, 2023
Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning.

Jonas B Nilsson, Saghar Kaabinejadian, Hooman Yari

|Sep 20, 2023
Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo.

Jesper van Eck van der Sluijs, Diede van Ens, Jolanda Brummelman

|Nov 28, 2022
Human T cells recognize HLA-DP-bound peptides in two orientations.

Sebastian Klobuch, Jia Jia Lim, Peter van Balen

|Nov 21, 2022
SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells.

Cilia R Pothast, Romy C Dijkland, Melissa Thaler

Pageof 2

Frequent Collaborators

5 joint publications

Mirjam H M Heemskerk

3 joint publications

Peter A van Veelen

3 joint publications

Peter van Balen

3 joint publications

J H Frederik Falkenburg